Plain-English translation of NCT06132984 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study follows women with gynecologic cancer who are about to start immune checkpoint inhibitor therapy—a newer type of cancer treatment that trains your immune system to fight cancer. Researchers want to understand how this medication affects heart health by taking specialized heart images and running heart tests before treatment starts, at several points during treatment, and for up to 2 years after. The goal is to spot any heart problems early and learn which test results might predict long-term outcomes.
Immune checkpoint inhibitors can sometimes cause heart problems as a side effect, but doctors don't yet have the best way to detect and predict these issues early. This study uses advanced heart imaging to better understand how this treatment affects individual hearts and to develop better warning signs that could help doctors protect patients.
You likely qualify if…
You likely don't qualify if…
You will have heart assessments before starting the medication, then again just before your 3rd and 5th treatment cycles, and again 1 year and 2 years after your first dose. Each assessment includes a heart imaging scan called cardiac magnetic resonance (CMR), an echocardiogram (ultrasound of the heart), blood tests to check for heart injury markers, and a clinical evaluation. After you stop the medication, you'll have one more heart assessment. The whole study follows you for up to 2 years to track your heart health and cancer outcomes.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
China